Janine Sengstack, PhD, is co-founder and CSO of Junevity, a longevity biotech developing Cell Reset siRNA therapeutics. Junevity’s RESET platform is the first to identify transcription factor targets for siRNA repression based on large-scale human data and AI. During her doctorate work in cellular aging at UC San Francisco (UCSF), Sengstack created the foundation for the Junevity RESET discovery platform and was the first to show repressing single transcription factor can reprogram gene expression to a healthy state. At Junevity, Sengstack leads development of the RESET discovery platform from concept through siRNA candidate nomination for clinical development. Her work to date includes promising programs in metabolism and neurodegenerative diseases.